Balyasny Asset Management
MDGL icon

Balyasny Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Balyasny Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$582K – 3257
2025
Q4 		$582K Sell
1,000
-1,600
-62% -$817K ﹤0.01% 2458
2025
Q3 		$1.19M Buy
+2,600
New +$970K ﹤0.01% 2043
2025
Q1 		– Sell
-1,300
Closed -$401K – 3096
2024
Q4 		$401K Sell
1,300
-8,900
-87% -$2.5M ﹤0.01% 2274
2024
Q3 		$2.16M Buy
+10,200
New +$2.61M ﹤0.01% 1633

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Balyasny Asset Management's MDGL Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 79,011 shares worth $42.4M. The stake represents 0.05% of the portfolio and ranks #416 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in MDGL as recently as Q3 2025.

Balyasny Asset Management first reported a position in MDGL in Q4 2022 and has held it in 8 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Balyasny Asset Management held 79,011 shares of Madrigal Pharmaceuticals worth $42.4M as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Balyasny Asset Management position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.05% of Balyasny Asset Management's portfolio in Q2 2026, its #416 holding.
  • Balyasny Asset Management first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.